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In response to DNA damage, the cell cycle checkpoint kinase 2 (CHEK2) may phosphorylate p53, Cdc25A and Cdc25C, and regulate
BRCA1 function, leading to cell cycle arrest and DNA repair. The truncating germline mutation CHEK2*1100delC abrogates kinase
activity and confers low-penetrance susceptibility to breast cancer. We found CHEK2*1100delC in 0.5% of 190 oesophageal
squamous cell carcinomas and in 1.5% of 196 oesophageal adenocarcinomas. In addition, we observed the mutation in 3.0% of 99
Barrett’s metaplasias and 1.5% of 66 dysplastic Barrett’s epithelia, both known precursor lesions of oesophageal adenocarcinoma.
Since CHEK2*1100delC mutation frequencies did not significantly differ among oesophageal squamous cell carcinomas,
adenocarcinomas and (dysplastic) Barrett’s epithelia, as compared to healthy individuals, we conclude that the CHEK2*1100delC
mutation has no major contribution in oesophageal carcinogenesis.
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Oesophageal carcinoma is the ninth most common tumour type
worldwide. Despite surgical intervention, 5-year overall survival is
less than 20%, mainly due to the fact that patients often present
with an advanced tumour stage. Alcohol and tobacco use are
established risk factors for the development of oesophageal
squamous cell carcinomas (Muir and McKinney, 1992). The
presence of Barrett’s oesophagus is the main risk factor for
adenocarcinoma formation, being 30–125 times higher in patients
with Barrett’s oesophagus, as compared to the general population.
Barrett’s oesophagus is defined as a columnar cell metaplasia of
the native distal oesophageal squamous cell epithelium (Spechler
and Goyal, 1986), accompanied by the presence of Goblet cells, as a
result of chronic gastro-oesophageal reflux. Barrett’s metaplasia
can progress to low- and high-grade dysplasia, and ultimately to
invasive and metastasising adenocarcinoma. Patients with Barrett’s
oesophagus receive endoscopic surveillance to detect dysplasia and
to diagnose carcinoma at an early and possibly treatable stage. The
identification of genes that confer susceptibility for adenocarci-
noma formation in Barrett’s oesophagus would imply improved
manageability of patients with Barrett’s oesophagus. Familial cases
of oesophageal cancer are however rare, and susceptibility genes
for oesophageal cancer are thus unlikely to be found by linkage
analysis. Consequently, screening of candidate susceptibility genes
may be a more feasible approach for oesophageal cancer.
CHEK2 (also known as CHK2) is the mammalian homologue of
Saccharomyces cerevisiae Rad53 and Schizosaccharomyces pombe
Cds1 genes (Matsuoka et al, 1998; Chaturvedi et al, 1999). The
CHEK2 gene, located on human chromosome 22q12, encodes a cell
cycle checkpoint kinase that is implicated in DNA damage
responses. Phosphorylation of the p53, Cdc25A and Cdc25C
protein results in arrests in various phases of the cell cycle (Zhou
and Elledge, 2000; Bartek et al, 2001). In addition, CHEK2 has been
implicated in the regulation of DNA repair by the BRCA1 protein
(Zhou and Elledge, 2000; Bartek et al, 2001). CHEK2*1100delC is a
truncating germline variant of CHEK2 that abrogates kinase
activity (Lee et al, 2001; Wu et al, 2001) and has initially been
reported in families suffering from the Li–Fraumeni syndrome
without p53 mutations (Bell et al, 1999). In familial gastric cancers,
which are known to cluster in Li–Fraumeni families, germline
CHEK2 mutations were absent (Kimura et al, 2000). In sporadic
(osteo)sarcomas, lung cancers, breast cancers, ovarian cancers,
colon cancers and haematopoietic neoplasms, CHEK2 was found to
be rarely mutated (Bell et al, 1999; Haruki et al, 2000; Hofmann
et al, 2001; Tavor et al, 2001; Aktas et al, 2002; Hangaishi et al,
2002; Ingvarsson et al, 2002; Miller et al, 2002). From recent
publications, it appeared that the germline CHEK2*1100delC
mutation in fact confers low-penetrance susceptibility to breast
cancer (Meijers-Heijboer et al, 2002; Vahteristo et al, 2002). An
increased frequency of CHEK2*1100delC was found among breast
carcinoma families without BRCA1 or BRCA2 mutations, asso-
ciated with an approximately two-fold increase of breast cancer
risk in female carriers (Meijers-Heijboer et al, 2002).
The p53 protein is one of the downstream targets of CHEK2
kinase. Mutations of the p53 gene result in a variety of
disturbances in growth control involving DNA replication, DNA
repair and apoptosis. Like in breast carcinoma, mutations of the
p53 gene appear to play an important role in the development of
oesophageal squamous cell carcinoma, dysplastic Barrett’s epithe-
lium and the progression to oesophageal adenocarcinoma (Casson
et al, 1991; Neshat et al, 1994; Wu et al, 1998). Ample studies have
reported mutations in p53 in oesophageal carcinomas, with
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smutation frequencies varying from 40 to 90% (Jankowski et al,
1999; Mandard et al, 2000; Wijnhoven et al, 2001; Jenkins et al,
2002). As CHEK2 and p53 are thought to be participants of the
same biological pathway, we aimed to establish whether
CHEK2*1100delC confers susceptibility to oesophageal cancer, by
determining the frequency of the mutation among an unselected
series of oesophageal cancers and precursor lesions.
MATERIALS AND METHODS
Tissue specimens and controls
We investigated a cohort of 190 oesophageal squamous cell cancer
patients, 196 oesophageal adenocarcinoma patients, 99 patients
with Barrett’s metaplasia and 66 patients with dysplastic Barrett’s
epithelium. Tissue samples were obtained from resection speci-
mens (carcinomas) or endoscopic biopsies (Barrett’s metaplasia
and dysplasia), all derived from different patients. We micro-
scopically confirmed that the endoscopic biopsy specimens did not
exhibit any tumour cell invasion. Tissue fragments were digested
from routine formalin-fixed, paraffin-embedded tissue blocks,
without deparaffinisation, in 180ml of 50mMl
 1 Tris/HCl
(pH¼8.0), and 20ml of Proteinase K (20mgml
 1) was added.
After overnight incubation at 561C, the lysates were boiled for
10min and subsequently centrifuged. The two series of Dutch
control individuals consisted of: (A) 184 spouses of individuals
heterozygous with respect to cystic fibrosis from the Southwest
Netherlands, and (B) 460 individuals at ages 55 and older,
ascertained through the Erasmus Rotterdam Health and the
Elderly Study (ERGO) (Meijers-Heijboer et al, 2002).
METHODS
Allele-specific oligonucleotide hybridisation assay
CHEK2 exon 10 was amplified using forward CHEK2 primer (50-
CAACATTATTCCCTTTTGTACTG-30) and reverse CHEK2 primer
(50-GTTCCACATAAGGTTCTCATG-30). DNA samples (1ml) were
subjected to PCR analysis in a total volume of 50ml containing 1 
Promega buffer, 1.5mM MgCl2-solution, 4mM dGTP, dTTP, dCTP
and dATP, 3U Taq DNA polymerase (Promega, Madison, USA),
and 0.2mg of forward and reverse CHEK2 primers. PCR
amplification consisted of 35 cycles (951C for 30s, 551C for 45s
and 721C for 45s), followed by a final extension at 721C for 10min.
We detected the CHEK2*1100delC mutation by application of
diluted PCR products to nylon filters and hybridisation under a
high stringency of [
32P]-labelled oligonucleotides complementary
to CHEK2*1100delC and the wild-type sequence (50-TTAGATTAT-
GATTTTGGG-30 and 50-TTAGATTACTGATTTTGG-30, respec-
tively).
Polymorphic marker analysis
DNA was radioactively amplified essentially, as described above,
using forward primer (50-TAAGGTGGGAGGTTCACTTG-30) and
reverse primer (50-ACCCATCCTCCTGCCTTAG-30) for the
D22S275 locus. PCR products were separated on a 6% poly-
acrylamide denaturing gel. After electrophoresis, gels were dried
on blotting paper and exposed to X-ray films. Films were evaluated
by visual inspection.
Immunohistochemistry
From formalin-fixed paraffin-embedded tissue blocks, 4-mm thick
sections were mounted on 3-aminopropyl-triethoxysilane (APES)-
coated glass slides. The sections were incubated with a mouse
monoclonal antibody DCS 270.1 against the human CHEK2 protein
(Novocastra Laboratories, Newcastle, UK; at a dilution of 1:50).
Immunoreactivity was visualised by a standard avidin biotin
immunoperoxidase technique, using a commercially available kit
(Labvision, Fremont, USA) (Bartkova et al, 2001; Lukas et al,
2001).
Statistics
Differences of the CHEK2*1100delC mutation frequency between
patients and controls were expressed in terms of odds ratios (OR)
and 95% confidence intervals (95% CI), and tested with the w
2-test.
RESULTS AND DISCUSSION
We analysed tumour and biopsy samples obtained from 551 Dutch
patients by a CHEK2*1100delC allele-specific oligonucleotide
hybridisation assay. CHEK2*1100delC mutations were detected in
0.5% of 190 squamous cell carcinomas, 1.5% of 196 adenocarci-
nomas, 3.0% of 99 Barrett’s metaplasias and in 1.5% of 66
dysplasias (Table 1). w
2 analysis revealed no significant differences
between patient groups and the CHEK2*1100delC mutation
frequency of 1.4% among 644 control individuals (P¼0.94), and
the odds ratio of the total patient group compared to the controls
was 1.04 (95% CI 0.35–3.06, Table 1). These results suggest that
CHEK2*1100delC does not substantially contribute to the devel-
opment of oesophageal carcinoma. CHEK2*1100delC could still
confer a three-fold risk, which is greater than the estimated two-
fold risk associated with breast cancer, and CHEK2*1100delC thus
may still be a low-penetrance susceptibility gene to oesophageal
cancer. Given the low frequency of the mutation, however, even the
maximal possible three-fold risk conferred by CHEK2*1100delC
would only marginally contribute to the overall incidence of
oesophageal cancer.
Examples of the hybridisation assay are shown in Figure 1. The
median ages of patient groups at diagnosis were 59.6, range 14–86
years (Barrett’s metaplasias), 60.3, range 32–84 years (dysplasias),
63.9, range 36–84 years (adenocarcinomas) and 60.9, range 31–79
years (squamous cell carcinomas). Ages at diagnosis of
CHEK2*1100delC mutation carriers were 48, 73 and 77 years
(Barrett’s metaplasias), 59 years (dysplasia), 44, 50 and 63 years
(adenocarcinomas) and 73 years (squamous cell carcinoma),
which were not different from noncarriers and, again, not
supporting a major role of CHEK2*1100delC in oesophageal
cancer predisposition.
Table 1 CHEK2*1100delC mutation frequencies
CHEK2*1100delC mutation
Number
tested Carriers Percentage
OR
(95% CI)
a P-value
a
Controls
Netherlands (A)
b 184 3 1.6
Netherlands
(B-ERGO)
b
460 6 1.3
Total 644 9 1.4
Barrett’s
metaplasias
99 3 3.0 2.20 (0.38–9.04) 0.23
Dysplasias 66 1 1.5 1.09 (0.02–8.05) 0.93
Adenocarcinomas 196 3 1.5 1.10 (0.19–4.45) 0.89
Squamous cell
carcinomas
190 1 0.5 0.37 (0.01–2.73) 0.33
Total 551 8 1.5 1.04 (0.35–3.06) 0.94
aOR: odds ratio, 95% CI: 95% confidence interval, and P-values are determined by
w
2-test, as compared to frequency in controls.
bCHEK2*1100delC frequency in Dutch
control cohorts A and B by Meijers-Heijboer et al (2002).
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sAll mutations were confirmed and proven to be germline-derived
by investigating patients’ normal tissues. Only paraffin-embedded
samples of tumour-negative lymph nodes were available, preclud-
ing confirmation of mutations by sequencing of long-range PCR
products (Sodha et al, 2002). The CHEK2*1100delC germline
mutation has, however, been found to be linked to one specific
allele of the D22S275 polymorphic marker, that is located in intron
4o fCHEK2, which is present in 13% of the Dutch population
(Meijers-Heijboer et al, 2002). All eight mutation-positive cases
were demonstrated to carry the D22S275 allele linked to the CHEK2
mutation, which supports the detected mutations (Figure 2).
Comparison of allele patterns in mutated tumours with their
normal tissues revealed LOH in only one of the three informative
carcinomas (T1 without LOH in Figure 2B, T4 with LOH in
Figure 2C). LOH was also observed in three out of 14 informative
nonmutated tumour samples. Limited data are, however, available
on LOH of CHEK2 in tumours, and the possible tumour-
suppressing role of CHEK2 therefore awaits further studies.
Immunohistochemistry using monoclonal antibody DCS 270.1
on a series of mutated and nonmutated tumour tissues showed
clear nuclear staining in all cases (Figure 3). Since the DCS 270.1
epitope lies within the N-terminus of CHEK2, staining of both
wild-type and mutant protein may be expected. We observed no
differences in CHEK2 protein levels, that is, neither lower intensity
nor a lower percentage of CHEK2-positive cells, between
CHEK2*1100delC mutated and nonmutated cancers. This was also
true for the single-mutated tumour with LOH (T4 in Figure 3f),
suggesting that a theoretical two-fold reduction in CHEK2 protein
level cannot be detected by the applied immunohistochemistry
method. This appears to contrast the results of Vahteristo et al,
who reported loss of expression in three of the four CHEK2*1100-
delC tumours and reduction of CHEK2 protein expression in the
fourth, using the same antibody (Vahteristo et al, 2002).
Comparison of the two studies is, however, difficult, as they did
Figure 1 Allele-specific oligonucleotide hybridisation assay of 94
adenocarcinomas. Blot (A), hybridisation with wild-type oligonucleotide.
Blot (B), hybridisation with mutant oligonucleotide. Adenocarcinoma
samples T1, T2 and T3 are positive for the CHEK2*1100delC mutation,
sample ‘þC’ represents a control individual with CHEK2*1100delC, and
sample ‘ C’ represents a control individual negative for CHEK2*1100delC.
Figure 2 D22S275 polymorphic marker analysis in samples with
CHEK2*1100delC. (A), the allele (arrow), known to be present in all
carriers of CHEK2*1100delC (18), is present in all samples with the
CHEK2*1100delC mutation (T1–T3 mutated adenocarcinoma samples,
T4 mutated squamous cell carcinoma, D1 mutated dysplastic tissue, M1–
M3 mutated metaplastic tissue), ‘þC’ represents a control individual with
CHEK2*1100delC. (B, C), LOH patterns from two mutated tumours (T1
adenocarcinoma and T4 squamous cell carcinoma) compared with the
corresponding normal tissues (N1 and N4) are shown. The arrowhead
points to the deleted allele in T4.
Figure 3 CHEK2 protein expression. Nonmutated squamous cell carcinoma in (A), nonmutated adenocarcinoma in (B). The remaining samples are from
the four mutated tumours: adenocarcinomas T1, T2 and T3 shown in (C–E), squamous cell carcinoma T4 shown in (F). Magnification  100 (B, E),  50
(A, C, D, F). Note the strong nuclear CHEK2 immunoreactivity in the tumour cells.
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(Vahteristo et al, 2002). Since only few CHEK2*1100delC tumours
have currently been reported, both the data of Vahteristo et al and
the present data should be interpreted with caution.
In summary, our study of a large and unselected series of
Barrett’s metaplasias and dysplasias, oesophageal adenocarcino-
mas and squamous cell carcinomas suggests that the germline
CHEK2*1100delC mutation has no major contribution in oeso-
phageal carcinogenesis.
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